- Conditions
- Solid Tumors
- Interventions
- Production of Genetically-modified T cells, Cyclophosphamide, IP Catheter Insertion, Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells, Fludarabine
- Procedure · Drug · Device + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 8,000
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Overactive Bladder With Urge Urinary Incontinence
- Interventions
- URO-902, Placebo
- Drug
- Lead sponsor
- Urovant Sciences GmbH
- Industry
- Eligibility
- 40 Years to 79 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 20
- States / cities
- Mobile, Alabama • Tucson, Arizona • Laguna Hills, California + 17 more
- Conditions
- Pre-eclampsia
- Interventions
- Placebo, RLX030
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Mobile, Alabama • Lexington, Kentucky • Louisville, Kentucky + 1 more
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Interventions
- UCART123
- Biological
- Lead sponsor
- Cellectis S.A.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Observational study no intervention
- Other
- Lead sponsor
- University Hospital, Basel, Switzerland
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • Miami, Florida + 11 more
- Conditions
- Advanced Non-hematologic Malignancies
- Interventions
- IXAZOMIB
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more
- Conditions
- Respiratory Syncytial Virus Infections, Virus Diseases
- Interventions
- JNJ-53718678, Placebo
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 1 Month to 24 Months
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Kirksville, Missouri
- Conditions
- Breast Cancer, Urothelial Carcinoma
- Interventions
- Trastuzumab deruxtecan, Nivolumab
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 10
- States / cities
- Santa Monica, California • New Haven, Connecticut • Miami, Florida + 7 more
- Conditions
- Hearing Loss, Geriatric Disorder
- Interventions
- Tele-HS, PCP encouragement
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years to 75 Years
- Enrollment
- 1,146 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • New Hyde Park, New York • New York, New York + 3 more
- Conditions
- DVT
- Interventions
- IVC filter removal
- Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Venous Thromboses
- Interventions
- Not listed
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Mild-Moderate Alzheimer's Disease, Healthy Elderly
- Interventions
- MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection, IV Placebo, Placebo for Subcutaneous Injection
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Glendale, California • Long Beach, California • Panorama City, California + 7 more
- Conditions
- Healthy
- Interventions
- Sampling Rate
- Other
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Interventions
- cyclophosphamide, cyclosporine, Fludarabine, mycophenolate mofetil, total marrow irradiation, umbilical cord blood transplantation, Granulocyte colony-stimulating factor, HLA-matched related donor bone marrow
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Healthy
- Interventions
- Efavirenz, Bupropion, Rosuvastatin, Montelukast
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Idiopathic Generalized Epilepsy
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 17
- States / cities
- San Francisco, California • New Haven, Connecticut • Washington D.C., District of Columbia + 12 more
- Conditions
- Multiple Sclerosis, Pregnancy
- Interventions
- Kesimpta
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 725 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2033
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Breast Cancer
- Interventions
- Basic public reporting, Enhanced intervention, Control group - observational
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 400,415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Unresectable Pancreatic Carcinoma
- Interventions
- Akt Inhibitor MK2206, Dinaciclib, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Denver, Colorado • Baltimore, Maryland + 1 more
- Conditions
- Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
- Interventions
- Durvalumab / Tremelimumab Combination Therapy
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- zocaglusagene nuzaparvovec
- Genetic
- Lead sponsor
- Astellas Gene Therapies
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2035
- U.S. locations
- 3
- States / cities
- Orange, California • Palo Alto, California • Salt Lake City, Utah
- Conditions
- Solid Tumor, Adult
- Interventions
- ASTX029
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 19
- States / cities
- Duarte, California • Los Angeles, California • Newport Beach, California + 13 more
- Conditions
- Lyphoma, B-Cell, Leukemia, B-cell, Multiple Myeloma, Hematologic Malignancies
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2050
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Safety
- Interventions
- SBT115301, Placebo
- Biological
- Lead sponsor
- Sonoma Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona